Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyfuse Biomedical KKFSE:4892 +0.18%52 Cash Ratio is 3.69 as of Jun. 2026, which is 36% below its 10-year median of 5.81. GuruFocus rates FSE:4892 with a GF Score™ of 52/100 and a GF Value™ of 円2,202.02 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 965 Drug Manufacturers companies, Cyfuse Biomedical KK ranks better than 88.6% on this metric.
Cyfuse Biomedical KK has a Cash Ratio of 3.69. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cyfuse Biomedical KK's Cash Ratio or its related term are showing as below:
FSE:4892'
s Cash Ratio Range Over the Past 10 Years
Min: 3.69 Med: 5.81 Max: 10.02
Current: 3.69
During the past 6 years, Cyfuse Biomedical KK's highest Cash Ratio was 10.02. The lowest was 3.69. And the median was 5.81.
FSE:4892's Cash Ratio is ranked better than 88.6% of 965
companies
in the Drug Manufacturers industry
Industry Median: 0.58
vs FSE:4892: 3.69
Cyfuse Biomedical KK (FSE:4892) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cyfuse Biomedical KK Cash Ratio Related Terms
Cyfuse Biomedical KK Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyfuse Biomedical KK (FSE:4892) has a Cash Ratio of 3.69 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cyfuse Biomedical KK and its competitors. This is 36% below median its historical median of 5.81. Over the past decade, Cyfuse Biomedical KK's Cash Ratio has ranged from 3.69 to 10.02. According to the industry distribution chart, Cyfuse Biomedical KK ranks #110 out of 965 companies in the Drug Manufacturers industry, placing it in the top 11.4%.
Is Cyfuse Biomedical KK's Cash Ratio too high?
Cyfuse Biomedical KK's current Cash Ratio of 3.69 is 36% below median its 10-year median of 5.81. Over the past 10 years, this metric has ranged from a low of 3.69 to a high of 10.02. The Drug Manufacturers industry median Cash Ratio is 0.58. Cyfuse Biomedical KK's value of 3.69 is 536.2% above this industry median. Based on the distribution chart, Cyfuse Biomedical KK ranks #110 out of 965 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #110 out of 965 companies for Cash Ratio. This places Cyfuse Biomedical KK in the top 11% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.58. Cyfuse Biomedical KK's value of 3.69 is 536.2% above this benchmark. Historically, Cyfuse Biomedical KK's own Cash Ratio has ranged from 3.69 to 10.02 over the past decade. While the company's 10-year median is 5.81 vs. the industry median of 0.58, Cyfuse Biomedical KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.58, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyfuse Biomedical KK's current Cash Ratio of 3.69 is 536.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Cash Ratio is 3.69, which is 36% below median its own 10-year median of 5.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (FSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,202.02, compared to a current price of 円561.00 — trading 74.5% below its estimated fair value. The current Cash Ratio is 3.69, which is 36% below median its 10-year median of 5.81 and 536.2% above the Drug Manufacturers industry median of 0.58. Cyfuse Biomedical KK's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cyfuse Biomedical KK (FSE:4892), the current Cash Ratio is 3.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円561.00 is trading 74.5% below its estimated GF Value™ of 円2,202.02.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for FSE:4892:
Cash Ratio: 3.69 (36% below median its 10-year median of 5.81)
GF Value™: 円2,202.02 vs. price of 円561.00 (74.5% below fair value)
Industry Position: 536.2% above the Drug Manufacturers median (#110 of 965)
No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
52GF Score
Get the complete analysis for FSE:4892
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4892 has been successfully added to your 
